+Follow
Lemoney
No personal profile
1
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
Lemoney
06-08 18:12
Ðḍcvf94
SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares
Lemoney
06-08 18:10
Great article, would you like to share it?
Nurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4088002913287910","uuid":"4088002913287910","gmtCreate":1624934889307,"gmtModify":1624934889307,"name":"Lemoney","pinyin":"lemoney","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.08","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":572994414109640,"gmtCreate":1780913570663,"gmtModify":1780913641570,"author":{"id":"4088002913287910","authorId":"4088002913287910","name":"Lemoney","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088002913287910","idStr":"4088002913287910"},"themes":[],"title":"","htmlText":"Ðḍcvf94","listText":"Ðḍcvf94","text":"Ðḍcvf94","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/572994414109640","repostId":"2641183483","repostType":2,"repost":{"id":"2641183483","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1780913155,"share":"https://ttm.financial/m/news/2641183483?lang=en_US&edition=fundamental","pubTime":"2026-06-08 18:05","market":"us","language":"en","title":"SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2641183483","media":"Reuters","summary":"SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares. SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.\n </li>\n<li>\n Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.\n </li>\n<li>\n Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SG Company S.p.A. Società Benefit published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20139_168495_2026_oneinfo.pdf), on June 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-06-08 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.\n </li>\n<li>\n Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.\n </li>\n<li>\n Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SG Company S.p.A. Società Benefit published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20139_168495_2026_oneinfo.pdf), on June 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLcbxqH4:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2641183483","content_text":"SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n \n\n\n SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.\n \n\n Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.\n \n\n Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.\n \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SG Company S.p.A. Società Benefit published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20139_168495_2026_oneinfo.pdf), on June 08, 2026, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":572992970432568,"gmtCreate":1780913409206,"gmtModify":1780913641465,"author":{"id":"4088002913287910","authorId":"4088002913287910","name":"Lemoney","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088002913287910","idStr":"4088002913287910"},"themes":[],"title":"","htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/572992970432568","repostId":"2641354107","repostType":2,"repost":{"id":"2641354107","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1780908396,"share":"https://ttm.financial/m/news/2641354107?lang=en_US&edition=fundamental","pubTime":"2026-06-08 16:46","market":"nz","language":"en","title":"Nurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche","url":"https://stock-news.laohu8.com/highlight/detail?id=2641354107","media":"Reuters","summary":"Shares of drug developer $Nurix Therapeutics(NRIX)$ up 47% at $21.58 premarket.Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to...","content":"<html><head></head><body><p style=\"text-align: left;\">Shares of drug developer <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> up 47% at $21.58 premarket.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/712c8791fa0aad9deaf3c023914a91f9\" data-align=\"center\" tg-width=\"705\" tg-height=\"825\"/><span></span></p><p style=\"text-align: left;\">Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to $2.3 bln.</p><p style=\"text-align: left;\">The deal focuses on blood cancer drug bexobrutideg; development costs for the drug will be covered 60% by Roche and 40% by Nurix.</p><p style=\"text-align: left;\">Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones.</p><p style=\"text-align: left;\">The deal is expected to close in the third quarter of 2026.</p><p style=\"text-align: left;\">As of last close, NRIX stock down 22.8% YTD.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-06-08 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">Shares of drug developer <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> up 47% at $21.58 premarket.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/712c8791fa0aad9deaf3c023914a91f9\" data-align=\"center\" tg-width=\"705\" tg-height=\"825\"/><span></span></p><p style=\"text-align: left;\">Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to $2.3 bln.</p><p style=\"text-align: left;\">The deal focuses on blood cancer drug bexobrutideg; development costs for the drug will be covered 60% by Roche and 40% by Nurix.</p><p style=\"text-align: left;\">Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones.</p><p style=\"text-align: left;\">The deal is expected to close in the third quarter of 2026.</p><p style=\"text-align: left;\">As of last close, NRIX stock down 22.8% YTD.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","RHHBY":"罗氏控股","NRIX":"Nurix Therapeutics"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nL6N42G0J3:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2641354107","content_text":"Shares of drug developer Nurix Therapeutics up 47% at $21.58 premarket.Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to $2.3 bln.The deal focuses on blood cancer drug bexobrutideg; development costs for the drug will be covered 60% by Roche and 40% by Nurix.Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones.The deal is expected to close in the third quarter of 2026.As of last close, NRIX stock down 22.8% YTD.","news_type":1,"symbols_score_info":{"NRIX":0.9,"RHHBY":2}},"isVote":1,"tweetType":1,"viewCount":13,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":572994414109640,"gmtCreate":1780913570663,"gmtModify":1780913641570,"author":{"id":"4088002913287910","authorId":"4088002913287910","name":"Lemoney","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088002913287910","idStr":"4088002913287910"},"themes":[],"title":"","htmlText":"Ðḍcvf94","listText":"Ðḍcvf94","text":"Ðḍcvf94","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/572994414109640","repostId":"2641183483","repostType":2,"repost":{"id":"2641183483","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1780913155,"share":"https://ttm.financial/m/news/2641183483?lang=en_US&edition=fundamental","pubTime":"2026-06-08 18:05","market":"us","language":"en","title":"SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2641183483","media":"Reuters","summary":"SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares. SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.\n </li>\n<li>\n Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.\n </li>\n<li>\n Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SG Company S.p.A. Società Benefit published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20139_168495_2026_oneinfo.pdf), on June 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-06-08 18:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.\n </li>\n<li>\n Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.\n </li>\n<li>\n Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.\n </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SG Company S.p.A. Società Benefit published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20139_168495_2026_oneinfo.pdf), on June 08, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nNDLcbxqH4:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2641183483","content_text":"SG Company corrects voting-share count, reporting 23.28% decrease in ordinary shares and 124.32% increase in multiple-vote shares\n \n\n\n SG Company corrected an earlier disclosure on its share capital and voting-rights structure following the issuance of multiple-vote shares.\n \n\n Ordinary shares decreased by 9,939,875 to 19,912,823; multiple-vote shares increased by 9,939,875 to 17,932,997.\n \n\n Total shares outstanding were unchanged at 37,845,820; the correction replaces an earlier, incorrect change figure of 10,632,810 shares.\n \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SG Company S.p.A. Società Benefit published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20139_168495_2026_oneinfo.pdf), on June 08, 2026, and is solely responsible for the information contained therein.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":26,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":572992970432568,"gmtCreate":1780913409206,"gmtModify":1780913641465,"author":{"id":"4088002913287910","authorId":"4088002913287910","name":"Lemoney","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4088002913287910","idStr":"4088002913287910"},"themes":[],"title":"","htmlText":"Great article, would you like to share it?","listText":"Great article, would you like to share it?","text":"Great article, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/572992970432568","repostId":"2641354107","repostType":2,"repost":{"id":"2641354107","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"pubTimestamp":1780908396,"share":"https://ttm.financial/m/news/2641354107?lang=en_US&edition=fundamental","pubTime":"2026-06-08 16:46","market":"nz","language":"en","title":"Nurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche","url":"https://stock-news.laohu8.com/highlight/detail?id=2641354107","media":"Reuters","summary":"Shares of drug developer $Nurix Therapeutics(NRIX)$ up 47% at $21.58 premarket.Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to...","content":"<html><head></head><body><p style=\"text-align: left;\">Shares of drug developer <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> up 47% at $21.58 premarket.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/712c8791fa0aad9deaf3c023914a91f9\" data-align=\"center\" tg-width=\"705\" tg-height=\"825\"/><span></span></p><p style=\"text-align: left;\">Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to $2.3 bln.</p><p style=\"text-align: left;\">The deal focuses on blood cancer drug bexobrutideg; development costs for the drug will be covered 60% by Roche and 40% by Nurix.</p><p style=\"text-align: left;\">Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones.</p><p style=\"text-align: left;\">The deal is expected to close in the third quarter of 2026.</p><p style=\"text-align: left;\">As of last close, NRIX stock down 22.8% YTD.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNurix Therapeutics Jumps 47% On $2 Billion Cancer Drug Agreement With Roche\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-06-08 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p style=\"text-align: left;\">Shares of drug developer <a href=\"https://laohu8.com/S/NRIX\">Nurix Therapeutics</a> up 47% at $21.58 premarket.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/712c8791fa0aad9deaf3c023914a91f9\" data-align=\"center\" tg-width=\"705\" tg-height=\"825\"/><span></span></p><p style=\"text-align: left;\">Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to $2.3 bln.</p><p style=\"text-align: left;\">The deal focuses on blood cancer drug bexobrutideg; development costs for the drug will be covered 60% by Roche and 40% by Nurix.</p><p style=\"text-align: left;\">Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones.</p><p style=\"text-align: left;\">The deal is expected to close in the third quarter of 2026.</p><p style=\"text-align: left;\">As of last close, NRIX stock down 22.8% YTD.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","RHHBY":"罗氏控股","NRIX":"Nurix Therapeutics"},"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260608:nL6N42G0J3:1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2641354107","content_text":"Shares of drug developer Nurix Therapeutics up 47% at $21.58 premarket.Co says it entered into a licensing and collaboration agreement with Swiss pharmaceutical giant Roche ROPC.S worth up to $2.3 bln.The deal focuses on blood cancer drug bexobrutideg; development costs for the drug will be covered 60% by Roche and 40% by Nurix.Nurix will receive $700 million upfront, with possible payouts for development, regulatory and sales milestones.The deal is expected to close in the third quarter of 2026.As of last close, NRIX stock down 22.8% YTD.","news_type":1,"symbols_score_info":{"NRIX":0.9,"RHHBY":2}},"isVote":1,"tweetType":1,"viewCount":13,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
